Skip to content

Axogen AXGN Other intangible assets—net

Other intangible assets—net at other companies

Stryker logo
StrykerSYK
$5.52B-10.0%
IAR
Integra LifeSciencesIART
$1.11B-6.9%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$31.67M-7.9%
Enovis logo
EnovisENOV
$1.19B-11.3%
Baxter International logo
Baxter InternationalBAX
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%
Enterprise value$2.2B+91.4%
P/S9.5×+4.0×

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's other intangible assets—net?
Axogen (AXGN) reported other intangible assets—net of $7.27M in Q1 2026.
How has Axogen's other intangible assets—net changed year-over-year?
Axogen's other intangible assets—net increased by 23.6% year-over-year, from $5.88M to $7.27M.
What is the long-term trend for Axogen's other intangible assets—net?
Over 5 years (2020 to 2025), Axogen's other intangible assets—net has grown at a 26.9% compound annual growth rate (CAGR), from $2.05M to $6.75M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.